LLY

905.92

-5.93%↓

JNJ

237.38

-1.88%↓

ABBV

211.46

-5.03%↓

NVS

150.87

-2.7%↓

AZN

188.68

-2.25%↓

LLY

905.92

-5.93%↓

JNJ

237.38

-1.88%↓

ABBV

211.46

-5.03%↓

NVS

150.87

-2.7%↓

AZN

188.68

-2.25%↓

LLY

905.92

-5.93%↓

JNJ

237.38

-1.88%↓

ABBV

211.46

-5.03%↓

NVS

150.87

-2.7%↓

AZN

188.68

-2.25%↓

LLY

905.92

-5.93%↓

JNJ

237.38

-1.88%↓

ABBV

211.46

-5.03%↓

NVS

150.87

-2.7%↓

AZN

188.68

-2.25%↓

LLY

905.92

-5.93%↓

JNJ

237.38

-1.88%↓

ABBV

211.46

-5.03%↓

NVS

150.87

-2.7%↓

AZN

188.68

-2.25%↓

Search

United Therapeutics Corp

Avatud

SektorTervishoid

525.82 -1.14

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

526.76

Max

540.84

Põhinäitajad

By Trading Economics

Sissetulek

26M

364M

Müük

-9.3M

790M

P/E

Sektori keskmine

19.192

61.417

Kasumimarginaal

46.102

Töötajad

1,400

EBITDA

61M

524M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+1.11% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

29. apr 2026

Turustatistika

By TradingEconomics

Turukapital

2B

23B

Eelmine avamishind

526.96

Eelmine sulgemishind

525.82

Uudiste sentiment

By Acuity

50%

50%

156 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

United Therapeutics Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. märts 2026, 22:42 UTC

Tulu

Prudential PLC 2025 Adjusted Operating Profit Rises

17. märts 2026, 21:40 UTC

Tulu

Alimentation Couche-Tard Records Higher Profit, Revenue in 3Q

17. märts 2026, 23:56 UTC

Market Talk

BHP's Next CEO Likely to Build On Existing Strategic Direction -- Market Talk

17. märts 2026, 23:46 UTC

Market Talk

Nikkei May Rise After Recent Selloffs -- Market Talk

17. märts 2026, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. märts 2026, 23:42 UTC

Market Talk

RBA's Return to Policy Tightening Will Work -- Market Talk

17. märts 2026, 23:38 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Before FOMC Decision -- Market Talk

17. märts 2026, 23:24 UTC

Market Talk

Global Energy Roundup: Market Talk

17. märts 2026, 23:24 UTC

Market Talk

New Woodside CEO Seen as Low-Risk Appointment -- Market Talk

17. märts 2026, 22:22 UTC

Market Talk

BHP Hands Reins to Growth-Focused Executive -- Market Talk

17. märts 2026, 22:20 UTC

Tulu

Prudential PLC 2025 New Business Profit $2.78B Vs. $2.46B >2378.HK

17. märts 2026, 22:20 UTC

Tulu

Prudential PLC 2025 Adj Operating Profit $3.31B Vs. $3.13B >2378.HK

17. märts 2026, 22:07 UTC

Tulu

Nvidia Says It Is Restarting Production of AI Chips for Sale in China -- WSJ

17. märts 2026, 22:05 UTC

Tulu

ZTO Express (Cayman): Frank Zhen Wei to Resign From Board

17. märts 2026, 22:04 UTC

Tulu

ZTO Express (Cayman): Board Approves Repurchase of Up to $1.5B of Shares Over Next 24 Months >ZTO

17. märts 2026, 22:03 UTC

Tulu

ZTO Express (Cayman) Raises Semiannual Dividend to 39c Vs. 30c >ZTO

17. märts 2026, 22:01 UTC

Tulu

ZTO Express (Cayman) 4Q Adj EPS 47c >ZTO

17. märts 2026, 22:01 UTC

Tulu

ZTO Express (Cayman) 4Q Rev $2.08B >ZTO

17. märts 2026, 22:01 UTC

Tulu

ZTO Express (Cayman) 4Q EPS 47c >ZTO

17. märts 2026, 21:26 UTC

Tulu

Oklo Stock Wavers After Earnings, but the Nuclear Start-Up Has Good News -- Barrons.com

17. märts 2026, 21:09 UTC

Tulu

Couche-Tard: 12 Company-Operated Stores Acquired During 3Q

17. märts 2026, 21:08 UTC

Tulu

Couche-Tard 3Q Consolidated Same-Store Merchandise Revenue Up 2% >ATD.T

17. märts 2026, 21:08 UTC

Tulu

Couche-Tard 3Q Adj EPS 81c >ATD.T

17. märts 2026, 21:07 UTC

Tulu

Couche-Tard 3Q EPS 82c >ATD.T

17. märts 2026, 21:06 UTC

Tulu

Couche-Tard 3Q Rev $21.8B >ATD.T

17. märts 2026, 21:05 UTC

Tulu

Couche-Tard 3Q Adj EPS 81c >ATD.T

17. märts 2026, 21:05 UTC

Tulu

Couche-Tard 3Q Rev $21.8B >ATD.T

17. märts 2026, 21:05 UTC

Tulu

Couche-Tard 3Q EPS 82c >ATD.T

17. märts 2026, 21:05 UTC

Tulu

Couche-Tard 3Q Net $757.2M >ATD.T

17. märts 2026, 20:50 UTC

Market Talk
Uudisväärsed sündmused

Energy & Utilities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

United Therapeutics Corp Prognoos

Hinnasiht

By TipRanks

1.11% tõus

12 kuu keskmine prognoos

Keskmine 546 USD  1.11%

Kõrge 705 USD

Madal 35 USD

Põhineb 13 Wall Streeti analüütiku instrumendi United Therapeutics Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

13 ratings

9

Osta

4

Hoia

0

Müü

Tehniline skoor

By Trading Central

292.345 / 309.245Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

156 / 351 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
help-icon Live chat